• 1
    The AGREE collaboration. Appraisal of Guidelines for Research and Evaluation (AGREE) Instrument. London: St George’s Hospital Medical School, 2001. (Cited 12 Oct 2004.) Also available from URL:
  • 2
    National Health and Medical Research Council. A Guide to the Development, Implementation and Evaluation of Clinical Practice Guidelines. Canberra: Commonwealth of Australia, 1999. (Cited 9 Dec 2004.) Also available from URL:
  • 3
    National Health and Medical Research Council. NHMRC Additional Levels of Evidence and Grades for Recommendation for Developers of Guidelines. Pilot Program. Canberra: Commonwealth of Australia, 2005. (Cited 9 May 2005.) Also available from URL:
  • 4
    Hakel-Smith N, Lewis NM. A standardized nutrition care process and language are essential components of conceptual model to guide and document nutrition care and patient outcomes. J Am Diet Assoc 2004; 104: 187884.
  • 5
    Splett PL. Cost Outcomes of Nutrition Intervention. Part 2. New York: Mead Johnson and Company, 1996.
  • 6
    Ferguson ML, Bauer J, Gallagher B, Capra S, Christie DR, Mason BR. Validation of a malnutrition screening tool for patients receiving radiotherapy. Australas Radiol 1999; 43: 3257.
  • 7
    Bauer J, Capra S. Intensive nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy—a pilot study. Support Care Cancer 2005; 13: 27074.
  • 8
    Read JA, Crockett N, Volker DH et al. Nutritional assessment in cancer—comparing the Mini-Nutritional Assessment (MNA) to the Scored Patient Generated Subjective Global Assessment (PGSGA). Nutr Cancer 2006; 53: 516.
  • 9
    Simons J, Schols A, Westerterp K, Ten Velde G, Wouters E. The use of bioelectrical impedance analysis to predict total body water in patients with cancer cachexia. Am J Clin Nutr 1995; 61: 7415.
  • 10
    Bauer J, Capra S, Davies PSW. Estimation of total body water from foot to foot bioelectrical impedance analysis in patients with cancer cachexia—agreement between prediction methods and deuterium oxide dilution. J Hum Nutr Diet 2005; 18: 295300.
  • 11
    Davidson W, Ash S, Capra S, Bauer J. Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr 2004; 23: 23947.
  • 12
    Bruera E, Carraro S, Roca E, Cedaro L, Chacon R. Association between malnutrition and caloric intake, emesis, psychological depression, glucose taste, and tumor mass. Cancer Treat Rep 1984; 68: 8736.
  • 13
    Fearon K, Von Meyenfeldt M, Moses A et al. The effect of a protein and energy dense, n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003; 52: 147986.
  • 14
    Wigmore SJ, Ross JA, Falconer JS et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996; 12 (Suppl. 1): S2730.
  • 15
    Persson C, Glimelius B, Ronnelid J, Nygren P. Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomised pilot study. Nutrition 2005; 21: 17078.
  • 16
    Jatoi A, Rowland K, Loprinzi CL et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004; 22: 246976.
  • 17
    Bruera E, Strasser F, Palmer JL et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 2003; 21: 12934.
  • 18
    Moses AWG, Slater C, Preston T, Barber MD, Fearon KCH. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 2004; 90: 9961002.
  • 19
    Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos NC, Kalfarentzos F. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer 1998; 82: 395402.
  • 20
    Bauer J, Capra S, Battistutta D, Davidson W, Ash S, on behalf of Cancer Cachexia Study Group. Compliance with nutrition prescription improves outcomes in patients with unresectable pancreatic cancer. Clin Nutr 2005; 24: 9981004.
  • 21
    DeWys WD, Begg C, Lavin PT et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69: 4917.
  • 22
    Ollenschlager G, Thomas W, Konkol K, Diehl V, Roth E. Nutritional behaviour and quality of life during oncological polychemotherapy: results of a prospective study on the efficacy of oral nutrition therapy in patients with acute leukaemia. Eur J Clin Invest 1991; 22: 54653.
  • 23
    Kern KA, Norton JA. Cancer cachexia. JPEN J Parenter Enteral Nutr 1988; 12: 28698.
  • 24
    Shike M. Nutrition therapy for the cancer patient. Hematol Oncol Clin North Am 1996; 10: 22134.
  • 25
    Grant M, Rivera L. Impact of dietary counselling on quality of life in head and neck patients undergoing radiation therapy. Qual Life Res 1994; 3: 778.
  • 26
    Ottery FD. Definition of standardized nutritional assessment and interventional pathways in oncology. Nutrition 1996; 12 (Suppl. 1): S1519.
  • 27
    Nitenberg G, Raynard B. Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol 2000; 34: 13768.
  • 28
    Palomares MR, Sayre JW, Shekar KC, Lillington LM, Chlebowski R. Gender influence of weight-loss pattern and survival of non-small cell lung carcinoma patients. Cancer 1996; 78: 211926.
  • 29
    Isenring E, Capra S, Bauer J. Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal, head or neck area. Br J Cancer 2004; 91: 44752.
  • 30
    De Blaauw I, Deutz NEP, Von Meyenfeldt MF. Metabolic changes in cancer cachexia—first of two parts. Clin Nutr 1997; 16: 16976.
  • 31
    Chen HC, Leung SW, Wang CJ, Sun LM, Fang FM, Hsu JH. Effect of megestrol acetate and prepulsid on nutritional improvement in patients with head and neck cancers undergoing radiotherapy. Radiother Oncol 1997; 43: 759.
  • 32
    McQuellon RP, Moose DB, Russell GB et al. Supportive use of megestrol acetate (Megace) with head/neck and lung cancer patients receiving radiotherapy. Int J Radiat Oncol Biol Phys 2002; 52: 118085.
  • 33
    Simons JP, Schols AM, Hoefnagels JM, Westerterp KR, Ten Velde GP, Wouters EF. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial. Cancer 1998; 82: 55360.
  • 34
    Moldawer LL, Copeland EM. Proinflammatory cytokines, nutritional support and the cachexia syndrome. Cancer 1997; 79: 182839.
  • 35
    Tisdale MJ. Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia. Nutrition 1996; 12: 5313.
  • 36
    Cohn SH, Gartenhaus W, Sawitsky A et al. Compartmental body composition of cancer patients with measurement of total body nitrogen, potassium and water. Metabolism 1981; 30: 2229.
  • 37
    Ferguson M, Capra S. Nutrition screening practices in Australian hospitals. Nutr Dieta 1998; 55: 15761.
  • 38
    Banks M. Nutrition screening and prevalence of malnutrition in an Australian public hospital: validation of a level one admission screen (Thesis). Brisbane: Queensland University of Technology, 1995.
  • 39
    Christensen KS, Gstundtner KM. Hospital-wide screening improves basis for nutrition intervention. J Am Diet Assoc 1985; 85: 7046.
  • 40
    American Dietetic Association. Identifying patients at risk: ADA’s definitions for nutrition screening and assessment. J Am Diet Assoc 1994; 94: 8389.
  • 41
    Jones JM. The methodology of nutritional screening and assessment tools. J Hum Nutr Diet 2002; 15: 5971.
  • 42
    Ferguson M, Bauer J, Banks M, Capra S. Development of a valid and reliable malnutrition screening tool for adult acute hospital patients. Nutrition 1999; 15: 45864.
  • 43
    Stratton RJ, Hackston A, Longmore D et al. Malnutrition in hospital outpatients and inpatients: prevalence, concurrent validity and ease of use of the ‘malnutrition universal screening tool’ (‘MUST’) for adults. Br J Nutr 2004; 92: 799808.
  • 44
    Rubenstein LZ, Harker JO, Salva A, Guigoz Y, Vellas B. Screening for undernutrition in geriatric practice: developing the short-form mini-nutritional assessment (MNA-SF). J Gerontol A Biol Sci Med Sci 2001; 56: M36672.
  • 45
    Kondrup J, Rasmussen HH, Hamberg O, Stanga Z, Ad Hoc ESPEN Working Group. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr 2003; 22: 32136.
  • 46
    Jeejeebhoy KN. Nutritional assessment. Nutrition 2000; 16: 58590.
  • 47
    Gibson R. Principles of Nutritional Assessment. Oxford: Oxford University Press, 1990.
  • 48
    Detsky AS, McLaughlin JR, Baker JP et al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr 1987; 11: 813.
  • 49
    Ottery FD. Patient-Generated Subjective Global Assessment. In: McCallumPD, PolisenaCG, eds. The Clinical Guide to Oncology Nutrition. Chicago: The American Dietetic Association, 2000; 1123.
  • 50
    Ottery F, Bender F, Kasenic S. The design and implementation of a model of nutritional oncology clinic. Oncol Issues Suppl 2002; 17: 38.
  • 51
    Persson C, Sjoden PO, Glimelius B. The Swedish version of the patient-generated subjective global assessment of nutritional status: gastrointestinal vs urological cancers. Clin Nutr 1999; 18: 717.
  • 52
    Bauer J, Capra S, Ferguson M. Use of the scored patient—generated subjective global assessment as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr 2002; 56: 77985.
  • 53
    Isenring E, Bauer J, Capra S. The scored Patient-generated Subjective Global Assessment (PG-SGA) and its association with quality of life in ambulatory patients receiving radiotherapy. Eur J Clin Nutr 2003; 57: 3059.
  • 54
    McCallum PD, Polisena CG, eds. The Clinical Guide to Oncology Nutrition. Chicago: The American Dietetic Association, 2000.
  • 55
    Evans WK, Nixon DW, Daly JM et al. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non small cell lung cancer. J Clin Oncol 1987; 5: 11324.
  • 56
    Wigmore SJ, Plester CE, Ross JA, Fearon KC. Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. Br J Surg 1997; 84: 1967.
  • 57
    Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994; 219: 32531.
  • 58
    Heymsfield S, Wang Z, Visser M, Gallagher D, Pierson R. Techniques used in the measurement of body composition: an overview with emphasis on bioelectrical impedance analysis. Am J Clin Nutr 1996; 64 (Suppl.): S47884.
  • 59
    Simons J, Schols A, Westerterp K, Ten Velde G, Wouters E. Bioelectrical impedance analysis to assess changes in total body water in patients with cancer. Clin Nutr 1999; 18: 359.
  • 60
    McMillan DC, Watson WS, Preston T, McArdle CS. Lean body mass changes in cancer patients with weight loss. Clin Nutr 2000; 19: 4036.
  • 61
    Isenring E, Bauer J, Davies P, Capra S. Evaluation of foot-to-foot bioelectrical impedance in oncology outpatients receiving radiotherapy to the head and neck areas. Eur J Clin Nutr 2004; 58: 4651.
  • 62
    Bauer J, Capra S, Davies PSW, Ash S, Davidson W. Estimation of total body water from bioelectrical impedance analysis in subjects with pancreatic cancer—agreement between three methods of prediction. J Hum Nutr Diet 2002; 15: 1858.
  • 63
    Aaronson NK, Ahmedzai S, Bergman B et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 36576.
  • 64
    Cella DF, Tulsky DS, Gray C. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 57079.
  • 65
    Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 66
    Capra S, Bauer J, Davidson W, Ash S. Nutritional therapy for cancer-induced weight loss. Nutr Clin Pract 2002; 17: 21013.
  • 67
    ASPEN Board of Directors and The Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr 2002; 26 (1 Suppl.): 1SA138SA.
  • 68
    Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998; 34: 5039.
  • 69
    Ross PJ, Ashley S, Norton A et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 2004; 90: 190511.
  • 70
    Dietitians Association of Australia. Dietitians Association of Australia position paper. Nutrition priorities in palliative care of oncology patients. Nutr Dieta 1994; 51: 923.
  • 71
    Jatoin A, Daly BD, Hughes VA, Dallal GE, Kehayias J, Roubenoff R. Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure? Ann Thorac Surg 2001; 72: 34851.
  • 72
    Staal-van den Brekel AJ, Schols AM, Dentener MA, Ten Velde GP, Buurman WA, Wouters EF. Metabolism in patients with small cell lung carcinoma compared with patients with non-small cell lung carcinoma and healthy controls. Thorax 1997; 52: 33841.
  • 73
    Reeves MM. Estimating patients’ energy requirements: cancer as a case study (PhD Thesis). Queensland University of Technology, 2004.
  • 74
    Meyer BJ, Mann NJ, Lewis JL, Milligan GC, Sinclair AJ, Howe PR. Dietary intakes and food sources of omega-6 and omega-3 polyunsaturated fatty acids. Lipids 2003; 38: 3918.
  • 75
    Endres S, Ghorbani R, Kelley VE et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids or the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320: 26571.
  • 76
    Tisdale MJ, Beck SA. Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol 1991; 41: 1037.
  • 77
    Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ. The effect on human tumor necrosis factor α and interleukin 1B production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 1996; 63: 11622.
  • 78
    Burns CP, Halabi S, Clamon GH et al. Phase 1 clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res 1999; 5: 39427.
  • 79
    Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 1999; 81: 8086.
  • 80
    Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KCH. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 2000; 36: 17784.
  • 81
    National Health and Medical Research Council. Draft Executive Summary of Nutrient Reference Values for Australia and New Zealand, Including Recommended Dietary Intakes. Canberra, Australia: Commonwealth Department of Health and Ageing; New Zealand: Ministry for Health, December 2004.
  • 82
    Food and Drug Administration. Agency Response Letter GRAS Notice No. GRN 000105. Xxxx: United States Food and Drug Administration, 2002. (Cited 16 May 2005.) Also available from URL:
  • 83
    Scientific Advisory Committee on Nutrition. Advice on Fish Consumption: Benefits and Risks. London: Stationery Office, 2004. (Cited 30 Nov 2005.) Also available from URL:
  • 84
    Food Standards Australia New Zealand. Mercury in Fish. 2004. (Cited 16 May 2005.) Also available from URL:
  • 85
    Begbie S, Kerestes Z, Bell D. Patterns of alternative medicine use by cancer patients. Med J Aust 1996; 165: 5458.
  • 86
    Miller M, Boyer M, Burstow P et al. The use of unproven methods of treatment by cancer patients: frequency, expectations, cost. Support Care Cancer 1998; 6: 33747.
  • 87
    MacLennan A, Wilson D, Taylor A. The escalating cost and prevalence of alternative medicine. Prev Med 2002; 35: 16673.
  • 88
    The Cancer Council Australia. Position Statement. Complimentary and Alternative Therapies. Australia: The Cancer Council, 2005.
  • 89
    Arnold C, Richter MP. The effect of oral nutritional supplements on head and neck cancer. Int J Radiat Oncol Biol Phys 1989; 16: 15959.
  • 90
    McCarthy D, Weihofen D. The effect of nutritional supplements on food intake in patients undergoing radiotherapy. Oncol Nurs Forum 1999; 26: 897900.
  • 91
    Ovesen L, Allingstrup L, Hannibal J, Mortensen EL, Hansen OP. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 1993; 11: 20439.
  • 92
    Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 2005; 23: 14318.
  • 93
    Gillbreath J, Inman-Felton AE, Johnson EQ, Robinson G, Smith KG, eds. Medical Nutrition Therapy Across the Continuum of Care—Client Protocols, 2nd edn. Chicago: The American Dietetic Association, 1998.
  • 94
    National Health and Medical Research Council. How to Use the Evidence: Assessment and Application of Scientific Evidence. Canberra: Commonwealth of Australia, 2000. (Cited 9 Dec 2004.) Also available from URL: